Global Information
회사소개 | 문의 | 비교리스트

기면증 : 파이프라인 리뷰

Narcolepsy - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 227548
페이지 정보 영문 86 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


기면증 : 파이프라인 리뷰 Narcolepsy - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 86 Pages

기면증이란 과다한 졸음, 낮에 빈번히 수면이 엄습하는 특징이 있는 수면 장애입니다. 주요 증상으로 주간과다수면(EDS) 및 탈력발작, 환각, 수면 마비(가위눌림) 등을 들 수 있습니다. 주요 치료법에는 라이프스타일의 개선 및 약물요법, 카운셀링 등이 있습니다.

세계 각국에서의 기면증 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

기면증의 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

기면증 : 기업에서 개발중인 치료제

기면증 : 대학/기관에서 연구중인 치료제

기면증 : 파이프라인 제품의 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

기면증 : 기업에서 개발중인 제품

기면증 : 대학/기관에서 연구중인 제품

기면증 치료제 개발에 참여하고 있는 기업

  • Bioprojet SCR
  • Evotec AG
  • Flamel Technologies S.A.
  • H.A.C. Pharma
  • Jazz Pharmaceuticals Plc
  • NLS Pharma Group
  • Sanofi
  • SK Biopharmaceuticals Co., Ltd.
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • Theranexus SAS

기면증 : 치료제 평가

  • 단일요법 제품
  • 병용 제품
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

약제 개요

기면증 : 최근 파이프라인 동향

기면증 : 휴지중인 프로젝트

기면증 : 개발이 중지된 제품

기면증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 16.06.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Narcolepsy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H1 2020
  • Narcolepsy - Pipeline by Axsome Therapeutics Inc, H1 2020
  • Narcolepsy - Pipeline by Balance Therapeutics Inc, H1 2020
  • Narcolepsy - Pipeline by Bioprojet SCR, H1 2020
  • Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Narcolepsy - Pipeline by Inexia Ltd, H1 2020
  • Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2020
  • Narcolepsy - Pipeline by NLS Pharma Group, H1 2020
  • Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
  • Narcolepsy - Pipeline by Orexia Ltd, H1 2020
  • Narcolepsy - Pipeline by Seelos Therapeutics, Inc., H1 2020
  • Narcolepsy - Pipeline by Suven Life Sciences Ltd, H1 2020
  • Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Narcolepsy - Pipeline by Theranexus SAS, H1 2020
  • Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, H1 2020
  • Narcolepsy - Pipeline by XW Laboratories Inc, H1 2020
  • Narcolepsy - Dormant Projects, H1 2020
  • Narcolepsy - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Narcolepsy - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Narcolepsy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H1 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 4, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Narcolepsy - Overview
    • Narcolepsy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Narcolepsy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Narcolepsy - Companies Involved in Therapeutics Development
    • Avadel Pharmaceuticals Plc
    • Axsome Therapeutics Inc
    • Balance Therapeutics Inc
    • Bioprojet SCR
    • F. Hoffmann-La Roche Ltd
    • Inexia Ltd
    • Jazz Pharmaceuticals Plc
    • NLS Pharma Group
    • Ono Pharmaceutical Co Ltd
    • Orexia Ltd
    • Seelos Therapeutics, Inc.
    • Suven Life Sciences Ltd
    • Takeda Pharmaceutical Co Ltd
    • Theranexus SAS
    • Vallon Pharmaceuticals Inc
    • XW Laboratories Inc
  • Narcolepsy - Drug Profiles
    • (flecainide acetate + modafinil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbaclofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dextroamphetamine IR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JZP-258 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mazindol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLS-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPN-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oxybate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentylenetetrazol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pitolisant hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • reboxetine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5256390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLS-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium oxybate ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVNG-3031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-925 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-994 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XWL-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YNT-185 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Narcolepsy - Dormant Projects
  • Narcolepsy - Discontinued Products
  • Narcolepsy - Product Development Milestones
    • Featured News & Press Releases
      • Mar 30, 2020: Harmony Biosciences highlights publication Of narcolepsy treatment scientific review in sleep medicine
      • Mar 25, 2020: Avadel Pharmaceuticals completes the REST-ON Phase 3 Pivotal trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
      • Mar 25, 2020: Jazz Pharmaceuticals announces FDA acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
      • Jan 22, 2020: Jazz Pharmaceuticals submits new drug application for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy
      • Dec 17, 2019: Avadel Pharmaceuticals completes enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
      • Dec 03, 2019: Axsome Therapeutics announces AXS-12 achieves primary endpoint in CONCERT phase 2 trial in Narcolepsy
      • Dec 02, 2019: Avadel Pharmaceuticals announces key appointments to leadership team to support continued transformation and the advancement of FT218
      • Nov 25, 2019: Avadel Pharmaceuticals achieves enrollment target in REST-ON phase 3 pivotal trial of FT218 for excessive daytime sleepiness and Cataplexy in patients with Narcolepsy
      • Nov 20, 2019: Harmony Biosciences announces publication of data in sleep from two clinical studies of WAKIX (pitolisant)
      • Oct 21, 2019: Axsome Therapeutics completes patient enrollment in the CONCERT Phase 2 trial of AXS-12 in narcolepsy
      • Oct 02, 2019: Axsome Therapeutics to Provide Update on AXS-12 at the 2019 Cantor Global Healthcare Conference
      • Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress
      • Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1
      • Sep 25, 2019: Jazz Pharmaceuticals presents positive JZP-258 phase 3 study data at World Sleep 2019
      • Sep 24, 2019: First patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q